Zollikon

Researchers are evaluating the effect of Xeomin injections compared to placebo injections for preventing chronic migraine. This Phase 3, randomized, double-blind, placebo-controlled trial includes an extension period and aims to measure changes in the number of monthly migraine days. Participants have chronic migraine and meet specific criteria related to headache frequency and migraine history. Participants receive Xeomin or placebo injections into muscles of the head and neck at pericranial and cervical points. The study includes two Xeomin dose groups and a placebo group during the controlled period, with all groups receiving Xeomin in the extension phase. Four treatments are given approximately 12 weeks apart over a total study duration of 52 to 55 weeks. Participants take part in 14 visits over the study period, with the first, last, and four treatment visits conducted in person and the remaining eight visits by phone or video call. Researchers collect headache and migraine data from diaries and assess changes in monthly migraine days as the primary outcome. Safety is monitored by tracking treatment-related adverse events throughout the trial.

Researchers are evaluating the use of Xeomin injections to prevent episodic migraine. This Phase 3 clinical trial compares Xeomin to placebo injections in the muscles of the head and neck to measure changes in the number of monthly migraine days. Participants have episodic migraine with or without aura, and the study aims to assess the efficacy and safety of different Xeomin doses over time. Participants receive a series of four Xeomin or placebo injections spaced about 12 weeks apart. The study includes two experimental groups receiving different Xeomin doses and a placebo group, followed by an extension period where some participants receive Xeomin. Injections are given at specific points around the head and neck. The trial lasts approximately 52 to 55 weeks, starting with a 4 to 5 week screening period. Participants attend about 14 visits, including the first and last visits and four treatment visits conducted on-site, with other visits done remotely by phone or video call. Researchers monitor changes in monthly migraine days, headache days, and medication use, as well as any treatment-related side effects throughout the study.

Researchers are investigating whether tailored axillary surgery TAS combined with axillary radiotherapy ART is better than the current standard treatment, axillary lymph node dissection ALND, for patients with clinically node-positive breast cancer undergoing upfront surgery. The study aims to see if TAS plus ART improves arm-related quality of life and reduces the occurrence of lymphedema two years after treatment. This question arises because ALND, although standard, can cause significant side effects, and TAS selectively targets affected lymph nodes with potentially less harm. Participants will be randomly assigned to one of two groups one receiving ALND, which involves removing lymphatic tissue within the axilla, and the other receiving TAS with ART, where surgery removes sentinel and suspicious lymph nodes followed by targeted axillary radiotherapy. All participants will also receive breast or chest wall irradiation after breast-conserving surgery. The study compares these approaches to assess their impact on arm health and quality of life. During the trial, participants will be followed for at least two years to assess changes in arm-related quality of life and monitor for lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations over this period. The study is sponsored by University Hospital Basel and aims to complete primary outcome assessments by the end of 2029, with overall study completion planned for 2037.

This research aims to evaluate the effectiveness of AZD5335 compared to standard treatments in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study focuses on whether AZD5335 improves progression-free survival PFS among participants with either high or low levels of folate receptor alpha FR. Approximately 1100 adult women will be enrolled and divided into two groups based on their FR levels. Participants will be randomized within each group to receive either AZD5335 or the relevant standard treatment. Those with high FR levels will receive AZD5335 or mirvetuximab soravtansine, while those with low FR levels will receive AZD5335 or a chemotherapy agent chosen by the investigator, including paclitaxel, pegylated liposomal doxorubicin, or topotecan. Treatments are given intravenously, and participants will continue treatment until disease progression or other reasons for stopping. During the study, participants will undergo regular tumor assessments to monitor disease status. Researchers will follow all participants over time to evaluate overall survival. Safety and efficacy data will be reviewed periodically by an independent committee. The primary outcome is progression-free survival, measured for up to about five years. The study completion is expected by late 2029.

Researchers are evaluating the Hospital at Home HaH concept, which provides hospital-level care to acutely ill patients in their own homes. This includes daily medical and nursing visits, infusions, physiotherapy, diagnostics, and cooperation with hospitals and home care services. The study aims to demonstrate that HaH care is effective, safe, cost-efficient, and associated with high patient satisfaction compared to regular inpatient hospital care. Two main pathways are studied admission avoidance, where stable patients are admitted directly to HaH, and early supported discharge, where hospital patients are discharged earlier to complete treatment at home. The study compares two groups about 100 participants receiving hospital-equivalent care at home and 100 receiving traditional inpatient hospital care. Treatments include daily visits by physicians and nurses, infusion therapies, physiotherapy, and diagnostic procedures like blood tests, urine tests, ultrasound, and electrocardiography. Care is provided in partnership with hospitals, office-based physicians, home care organizations, and therapy providers. Both groups are monitored for treatment duration, therapy type, complications, and other health services used. Participants will be assessed for costs, mortality, rehospitalization, complications, patient satisfaction, length of stay, referrals to nursing homes or rehabilitation, and follow-up care. Data will be collected over one year or until 200 participants are included. The study will also track emergency department visits and home care types. Participants will complete questionnaires and be monitored for safety and outcomes throughout the study period, which starts in September 2025 and ends in August 2026.

Researchers are evaluating how different virtual landscape environments affect gait therapy in older adults with walking instability. The study focuses on the impact of urban, rural, and forest scenes viewed through virtual reality VR goggles during gait training. The goal is to understand how these environments influence stress reduction, attention restoration, and changes in walking patterns to improve gait stability. Participants will be randomly assigned to one of four groups three intervention groups using VR-assisted gait therapy in forest, urban, or rural landscapes, and a control group receiving standard gait therapy. Those in the VR groups will attend five training sessions within ten days, each lasting 25 minutes, including sitting and walking phases within the virtual environments. Walking aids may be used as needed during the sessions. During the study, participants will undergo assessments of stress levels, attention, and gait parameters before and after the intervention. Measurements include heart rate variability, skin conductance, gait speed, variability, and asymmetry, as well as interviews and eye-tracking during sessions. The study aims to identify which virtual landscapes best support gait stability by promoting stress relief and attention recovery. Participation spans the initial and final testing days, with training sessions occurring between these points.

This research focuses on postpartum hemorrhage PPH, a major cause of maternal illness and death worldwide, defined as blood loss of 500 mL or more within 24 hours after delivery. The study aims to determine if early replenishment of coagulation factor XIII FXIII can reduce postpartum blood loss and related complications. Current treatments mainly focus on fibrinogen replacement, but evidence for its effectiveness is inconclusive, prompting investigation of FXIIIs role based on previous studies showing its association with blood loss. Women who experience PPH with measured blood loss of at least 500 mL receive 1g of tranexamic acid intravenously as standard care. If bleeding continues and exceeds 700 mL, participants are randomly assigned to one of two groups the intervention group receives FXIII Fibrogammin intravenously at doses based on weight in addition to standard care, while the control group receives standard care alone. This is a nationwide, multi-center, open-label, randomized controlled trial conducted in perinatal centers across Switzerland. Participants will be monitored for blood loss during the first 24 hours after delivery as the primary outcome. Additional assessments include clinical outcomes of PPH at around 48 hours postpartum, changes in blood tests such as hemoglobin and platelet counts before delivery and at 48 hours, hospital costs, breastfeeding status at 6 to 9 weeks, and patient surveys shortly after hospital discharge. The study includes safety monitoring and follow-up during hospital stay and beyond, with participation lasting up to nine weeks after delivery.

Gastroentero-pancreatic neuroendocrine tumours GEP-NETs are rare cancers arising from the neuroendocrine cells in the gastrointestinal tract and pancreas. These tumours share common clinical features but their cell biology and mechanisms are not well understood, limiting targeted treatments. The SwissNET registry is designed to collect detailed information to better understand GEP-NETs and improve management strategies in Switzerland. This study collects data prospectively from patients diagnosed with neuroendocrine tumours confirmed by tissue analysis, regardless of the tumours original location. Data entry is anonymized and gathered from hospitals and general practitioners across Switzerland. A study nurse visits contributing centers to review patient files, and a review board addresses conflicting information. The registry monitors treatment approaches including surgery, medical therapy, and peptide-receptor radionuclide therapy. Participants provide informed consent for their data to be included. Researchers regularly evaluate patient outcomes such as tumour-related mortality and hospitalisation rates every five years. The registry also tracks the incidence of GEP-NETs in Switzerland and the effects of different treatments over time. This ongoing data collection aims to improve understanding and guide future care for patients with neuroendocrine tumours.